Cresco Labs has completed the acquisition of PharmaCann Penn, LLC for $50 million, marking its entry into Pennsylvania’s medical marijuana market. The transaction, settled on a cash-free, debt-free basis with normalized working capital, was financed through cash and a seller note.
The deal includes nine operational retail dispensaries, reinforcing Cresco’s position as both a retailer and wholesaler in Pennsylvania. The company plans to integrate the assets under its Sunnyside brand, maintaining existing cultivation and wholesale operations. Cresco’s brand portfolio already encompasses Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindy’s, and Remedi.
Pennsylvania’s medical cannabis sector generated over $1.1 billion in annual sales last year, according to Hoodie Analytics. Cresco expects the acquisition to enhance revenue, margins, and cash flow, aligning with its strategy of deploying capital into high-return opportunities. The transaction follows the company’s prospectus supplement dated January 29, 2026, filed under its base shelf prospectus from October 3, 2025.
